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Recent experiments have identified LXRa, a nuclear
hormone receptor that binds oxysterols, as a key
regulator of hepatic cholesterol homeostasis.
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The amount of cholesterol in animal cell membranes is
tightly regulated to maintain proper cell function.
Experiments performed over the past several years have
shown that this regulation occurs in large part through
transcription factors that control the expression of genes
involved in cholesterol metabolism. The ‘sterol regulatory
element binding proteins’ (SREBPs) are a class of
transcription factors that control a feedback pathway
influencing cholesterol biosynthesis and receptor-
mediated cholesterol uptake. Recent studies have now
identified the nuclear hormone receptor known as ‘liver X
receptor α’ (LXRα) as a second major transcription factor
involved in hepatic cholesterol homeostasis. LXRα
appears to activate a feed-forward pathway of cholesterol
catabolism. As several specific oxygenated sterols —
oxysterols — have been found to be ligands for LXRα,
these studies strongly implicate oxysterols as important
regulators of cholesterol homeostasis.
Cholesterol homeostasis and the oxysterol hypothesis
The liver uses many homeostatic pathways to maintain
optimal cellular cholesterol levels. Inside a liver cell,
cholesterol can be synthesized de novo from acetate or
taken up from plasma lipoproteins, which acquire
cholesterol from the diet or from peripheral tissues.
Lipoprotein uptake can occur either through receptor-
mediated endocytosis, as in the case of low density
lipoproteins (LDLs), or from the selective transfer of
cholesterol esters into the cell, as in pathways involving
the scavenger receptor BI. Hepatic cellular cholesterol has
a number of possible fates: it can be esterified by acyl-
CoA:cholesterol acyltransferases (ACATs) to form choles-
terol esters; be secreted from the cell by incorporation into
secreted lipoproteins or through efflux from the plasma
membrane; or undergo catabolism to form bile acids. The
liver represents the primary route of cholesterol excretion
from the body, as both cholesterol and bile acids are
secreted into the bile.
It has long been known that feeding cholesterol to
animals profoundly affects liver cholesterol metabolism.
Studies early in this century showed that excess dietary
cholesterol markedly suppresses hepatic cholesterol
biosynthesis. This inhibition occurs primarily through
the downregulation of the rate-limiting enzyme in cho-
lesterol biosynthesis, 3-hydroxy-3-methylglutaryl (HMG)
CoA reductase. But whether cholesterol itself, or oxy-
genated derivatives of cholesterol, are the effector mole-
cules in these regulatory processes has long been a matter
of debate. 
As cholesterol is insoluble in an aqueous environment and
resides mainly in membranes, it has been difficult to
imagine how it could function as a molecular regulator.
Oxysterols, on the other hand, have emerged as potential
homeostatic regulators because of their greater polarity
and aqueous solubility, and because of observations dating
from the 1970s that these compounds are more potent
than cholesterol in downregulating cholesterol biosynthe-
sis in cultured cells [1,2]. A cytosolic oxysterol-binding
protein was identified in the 1980s [3,4], but its function
remains uncertain. Despite many studies, direct proof that
oxysterols participate in cholesterol homeostasis has, until
now, been lacking.
SREBPs: key regulators of cholesterol metabolism
In the past several years, work that originated largely in
the laboratory of Brown and Goldstein has identified the
SREBPs as important regulators of cholesterol biosynthe-
sis (reviewed in [5]; see Table 1). Located in the endo-
plasmic reticulum (ER) of cells, these membrane-bound
transcription factors are activated by a proteolytic cleavage
that releases the amino-terminal portion of the molecule,
which subsequently localizes to the nucleus and acts as a
transcription factor. The target genes include those encod-
ing enzymes of the cholesterol biosynthesis pathway, such
as HMG CoA reductase, HMG CoA synthase, farnesyl
diphosphate synthase and squalene synthase, the LDL
receptor gene and genes encoding enzymes involved in
fatty acid synthesis and uptake, such as acetyl CoA car-
boxylase, fatty acid synthase and lipoprotein lipase. 
There are two known members of the SREBP family:
SREBP-1, which has the two splice variants SREBP-1a
and SREBP-1c, and SREBP-2. In the livers of animals,
SREBP-1 appears to participate more in the regulation of
fatty acid synthesis and SREBP-2 in cholesterol biosyn-
thesis. The in vivo importance of the SREBPs has been
demonstrated in cultured cells, for example by studies of
chinese hamster ovary (CHO) cells that are deficient in or
express constitutively activated versions of SREBPs, and
in transgenic animals [5,6].
The proteolytic activation of SREBPs is regulated by
another membrane-bound protein, the ‘SREBP cleavage
activating protein’ (SCAP) [5]. SCAP has a putative sterol-
sensing domain that presumably monitors the membrane
sterol concentration. The current hypothesis is that
changes in membrane sterol levels somehow alter the
interactions between SCAP and SREBPs. When mem-
brane sterols are low, SREBP is subsequently cleaved by
two proteases, and its amino-terminus migrates to the
nucleus. It is not yet known whether SCAP responds to
changes in the levels of membrane cholesterol, oxysterols
or both, nor is it known how SCAP senses changes in the
levels of the sterols that serve as regulatory signals.
LXRa: a feed-forward regulator of cholesterol homeostasis
In addition to a feedback suppression of cholesterol
biosynthesis, the hepatic response to excess cellular
cholesterol also involves an upregulation of bile acid
synthesis and secretion, the main pathway of cholesterol
catabolism. Several in vivo studies have demonstrated that
feeding cholesterol stimulates the transcription of the
gene for cholesterol 7α-hydroxylase, the rate-limiting
enzyme in the conversion of cholesterol to bile acids.
Recent experiments have now implicated a newly identi-
fied transcription factor, LXRα, as a key regulator of this
feed-forward pathway (Table 1).
LXRα was initially identified, by cDNA cloning from
human liver, as an orphan member of the nuclear hormone
receptor superfamily — that is, its functions and ligands
were at that point unknown [7]. Like many nuclear
hormone receptors, LXRα functions as a heterodimer with
the retinoid X receptor (RXR). The LXRα–RXR complex
activates transcription by binding to specific DNA-
response elements composed of a direct repeat of two
hexads separated by a four-nucleotide spacer. This
recognition site closely resembles the binding sites for
other nuclear hormone receptors.
The first clue that LXRα might be involved in cholesterol
metabolism came from the discovery that a subset of 
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Table 1
Two transcription factors involved in cholesterol homeostasis.
Transcription factor Location Activator Mechanism of activation Main effects
SREBPs ER membrane-bound Cholesterol? SCAP-mediated cleavage ↑ Cholesterol 
Oxysterols? → migration of amino terminus biosynthesis genes
to nucleus ↑ LDL receptor
LXRα Nuclear hormone Oxysterols Oxysterol ligand binding ↑ Bile acid 
receptor synthesis
Figure 1
Chemical structures of cholesterol and three
oxysterols that are ligands for LXRα. 
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naturally occurring oxysterols specifically activate this tran-
scription factor when tested in vitro at physiological con-
centrations [8,9]. These potent oxysterol activators of
LXRα include 24,25(S)-epoxycholesterol, which is pro-
duced from a shunt in the mevalonate synthesis pathway
and is present in the liver; 22(R)-hydroxycholesterol, a
product of sterol metabolism found in the adrenal glands;
and 24(S)-hydroxycholesterol, which is known as ‘cere-
brosterol’ owing to its high concentration in brain tissue
extracts (Figure 1). Further evidence came from the obser-
vation that the promoter region of the cholesterol 7α-
hydroxylase gene includes a functional LXRα response
element, suggesting that LXRα has a role in the regulation
of bile acid metabolism [9]. LXRα was shown to be most
highly expressed in the liver, the central organ of choles-
terol homeostasis, and in metabolically active tissues such
as the kidney, intestine, spleen and adrenal glands [7].
The recent generation of LXRα knockout mice by
Mangelsdorf and colleagues [10] has now established a
central role for LXRα in mammalian cholesterol metabo-
lism. The homozygous mutant (LXRα–/–) mice were
ostensibly healthy when fed a normal chow diet. In
response to a diet rich in cholesterol, however, LXRα–/–
mice failed to show the normal increase in bile acid syn-
thesis and secretion. After a few days, massive amounts of
cholesterol esters began to accumulate in their livers.
Their livers increased in size and, after three months on
the high-cholesterol diet, showed evidence of hepatocel-
lular degeneration and inflammation, leading ultimately to
hepatic dysfunction. As expected, the impaired bile acid
synthesis was accompanied by a failure to upregulate tran-
scription of the cholesterol 7α-hydroxylase gene. LXRα–/–
mice also failed to show the normal lowering of the ratio of
cholate to murocholate in the bile when fed a high-choles-
terol diet. This alteration in bile acid composition nor-
mally reduces the absorption of intestinal cholesterol in
wild-type animals.
The disruption in bile acid metabolism is not the only
homeostatic alteration caused by the absence of LXRα.
The cholesterol biosynthetic enzymes and SREBP-2 were
transcriptionally upregulated in LXRα–/– mice fed a chow
diet, but not in wild-type controls. Associated with this,
hepatic cholesterol levels were slightly, but significantly,
higher in mutant than in wild-type mice, suggesting that
LXRα may also be involved in feedback suppression of
cholesterol biosynthesis. In this regard, it is noteworthy
that inhibitors of HMG CoA reductase have recently been
shown to suppress LXRα activity, and that distinct
products of mevalonate metabolism can either stimulate or
inhibit LXRα activity in cultured cells [11]. 
In contrast to the apparent upregulation of hepatic
cholesterol biosynthesis observed in LXRα–/– mice fed a
chow diet, normal suppression of cholesterol biosynthesis
occurred in mutant mice fed a high-cholesterol diet,
presumably via inhibition of the SREBP pathway. Unex-
pectedly, however, plasma LDL–cholesterol levels were
increased in the LXRα–/– mice fed a high-cholesterol diet.
The reason for this phenotype is currently unclear, as
LDL receptor and apolipoprotein gene expression were
not altered in LXRα–/– mice. Lastly, it appears that LXRα
also acts to stimulate fatty acid synthesis, as transcription
of the genes for SREBP-1 and for some fatty acid syn-
thetic enzymes was found to be downregulated in
LXRα–/– mice. The concomitant regulation of cholesterol
biosynthesis and fatty acid synthesis is a recurring theme
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Figure 2
An overview of the hepatic response to
increased dietary cholesterol intake. Under
conditions of increased dietary cholesterol,
hepatic levels of cholesterol and, presumably,
oxysterols increase. As a result, SCAP-
mediated SREBP cleavage activation is
reduced, causing the transcriptional
downregulation of cholesterol biosynthesis
genes. LDL receptor gene expression is also
decreased, although this is not consistently
observed in all species. In parallel, LXRα is
activated, upregulating the synthesis and
secretion of bile acid. Sterol esterification by
the ACAT enzyme increases as well. Other
possible effects of sterol excess include an
LXRα-mediated upregulation of fatty acid
synthesis. SREBP, sterol regulatory element
binding protein; SCAP, SREBP cleavage
activating protein; LDL, low density
lipoprotein; ACAT, acyl-CoA:cholesterol
acyltransferase; LXRα, liver X receptor α.
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in cellular lipid biology [5] and may reflect the need for
cells to adjust in parallel their membrane cholesterol and
phospholipid content.
Hepatic response to dietary cholesterol
The new observations on LXRα–/– mice strongly impli-
cate oxysterols as physiologic regulators of cholesterol
homeostasis; they have also enhanced our understanding
of the hepatic response to dietary cholesterol. A current
perspective on this response is summarized in Figure 2.
These recent findings also, however, highlight the com-
plexity of cellular cholesterol regulatory mechanisms and
raise key questions. Are oxysterols also involved in the
SCAP-mediated regulation of cholesterol biosynthesis?
Which oxysterols are biologically relevant? How do cellu-
lar oxysterol levels relate to cellular cholesterol levels?
How does LXRα modulate plasma LDL–cholesterol
levels? Studies in progress, facilitated by the availability of
probes and reagents for the newly discovered transcription
factors involved in cholesterol homeostasis, are likely to
provide answers to these questions.
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